摘要:
Objective To study and analyze the clinical effect of valsartan on chronic pulmonary heart disease. Methods 100 cases of heart failure patients with pulmonary heart disease treated in our hospital from January 2015 to October 2016 were selected and randomly divided into the control group and the experimental group,50 cases in each group.Two groups of patients were given the basic treatment of diuretics,low salt diet, digitalis and nitrates,so as to ensure that the patients had enough rest.Patients in the control group were treated with benazepril,and the patients in the experimental group were treated with valsartan.The clinical indexes of the experimental group and the control group were compared and analyzed. Results After corresponding treatment,the number of effective treatment was 48 cases.In the control group,the total effective number was 41 cases. The effective rate of the control group (82.0%) was significantly lower than the experimental group(96.0%) (P<0.05).The incidence of adverse reactions in the experimental group was 8.0%, and the fatality rate was 10.0%. The incidence of adverse reactions in the control group was 10.0%, and the fatality rate was 12.0%.There was no significant difference between two groups.After treatment,the indexes of LVEDD and LVESD in the experimental group were better than those in the control group,with statistical significance(P<0.05).Conclusion Valsartan was effective in the treatment of chronic pulmonary heart disease with heart failure.It can improve the treatment efficiency and security in a certain extent,and has the significance of further popularization and application.%目的 研究分析缬沙坦对慢性肺心病心力衰竭的临床疗效观察.方法 选取本院2015年1月~2016年10月收治的100例肺心病心力衰竭患者为研究对象,随机分为对照组和试验组,每组各50例.给予2组患者利尿剂、低盐饮食、洋地黄以及硝酸酯类药物等基础治疗,保证患者有足够的休息.对照组患者给予贝那普利治疗,试验组患者给予缬沙坦治疗.比较分析试验组与对照组患者的相关临床指标.结果 经过对应的治疗后,试验组患者中,治疗有效例数为48例.对照组患者中,治疗总有效例数为41例.试验组患者的治疗有效率为96.0%,对照组患者治疗有效率为82.0%.可得,对照组患者的治疗有效率显著低于试验组,差异具有统计学意义(P<0.05).试验组患者不良反应发生率为8.0%,病死率为10.0%.对照组不良反应发生率为10.0%,病死率为12.0%.试验组与对照组患者的不良反应发生率以及病死率均差异无统计学意义.治疗后,试验组患者的LVEDD以及LVESD等指标均优于对照组,差异具有统计学意义(P<0.05).结论 缬沙坦对慢性肺心病心力衰竭的临床疗效较好,能够在一定程度上提高治疗有效率,安全性较高,具有临床进一步推广和应用的意义.